Zentalis Pharmaceuticals, Inc. SEC filings document clinical oncology disclosures, financial results, governance matters and capital actions for the ZNTL public company. Recent Form 8-K filings cover azenosertib program updates, Regulation FD corporate presentations, clinical-trial and scientific-presentation exhibits, and results of operations furnished with business updates.
The company’s proxy materials describe board composition, executive compensation, equity awards and shareholder voting matters. Other event filings also record corporate governance changes and completed common stock repurchase activity, alongside cautionary risk language related to clinical development, regulatory pathways and forward-looking statements.
Zentalis Pharmaceuticals, Inc. Schedule 13G reports that Squadron Master Fund LP (and related advisor and partners) beneficially hold 3,676,900 shares of common stock, representing 5.1% of the class.
The filing states this percentage is based on 72,250,779 shares outstanding as of November 1, 2025. The reporting persons disclose shared voting and shared dispositive power over the 3,676,900 shares and include a Rule 13d-4 disclaimer of beneficial ownership.
Zentalis Pharmaceuticals chief medical officer Ingmar Bruns reported automatic sales of company common stock to cover tax withholding on vested restricted stock units. On February 6, 2026, 2,962 shares were sold at $2.4297 per share, followed by 335 shares at $2.3929 per share on February 9, 2026. After these transactions, Bruns beneficially owned 33,332 shares of Zentalis common stock directly.
Zentalis Pharmaceuticals officer Vincent Vultaggio, who serves as PAO and PFO, reported several sales of company common stock. On February 6, 2026, he sold 29,951 shares at $2.4297 per share. On February 9, 2026, he sold 3,379 shares at $2.3929 per share, and on February 10, 2026, he sold 6,894 shares at $2.4223 per share. A footnote explains the first sale was made automatically by the company to cover tax withholding on vesting restricted stock units, while the later sale was executed under a pre-established Rule 10b5-1 trading plan. After these transactions, Vultaggio directly held 146,506 shares of Zentalis common stock.
Zentalis Pharmaceuticals, Inc. reported an insider transaction by its CEO & President and director, Julia Marie Eastland. On February 6, 2026, 7,866 shares of common stock were sold at $2.4297 per share, leaving 80,022 shares owned directly. On February 9, 2026, a further 889 shares were sold at $2.3929 per share, leaving 79,133 shares owned directly.
According to the footnote, these sales were made automatically by the issuer to cover tax withholding obligations arising from the vesting and settlement of restricted stock units previously granted to Eastland, rather than discretionary open-market sales.
Zentalis Pharmaceuticals officer Vincent Vultaggio reported two sales of common stock. On February 2, 2026, he sold 2,540 shares at $2.55 per share, an automatic sale by the company to cover tax withholding on vested restricted stock units.
On February 3, 2026, he sold 556 shares at $2.515 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he beneficially owned 186,730 shares of Zentalis common stock in direct form.
Zentalis Pharmaceuticals, Inc. reported that officer Vincent Vultaggio received a stock option grant for 100,000 shares on January 8, 2026. The options have an exercise price of $2.84 per share and expire on January 7, 2036. Following this grant, he beneficially owns 100,000 stock options directly.
According to the footnote, the options vest over four years in substantially equal monthly installments, and vesting depends on his continued service with the company. This structure ties the long-term value of the award to his ongoing tenure and the company’s future performance.
Zentalis Pharmaceuticals reported an equity award to its Chief Legal Officer, James B. Bucher. He received a stock option grant covering 100,000 shares of common stock at an exercise price of $2.84 per share. The options were granted on January 8, 2026 and are held directly. Following this grant, Bucher beneficially owns 100,000 stock options.
The options will vest over four years in substantially equal monthly installments, and vesting is conditioned on his continued service with the company. This is a compensatory award rather than an open-market purchase or sale.
Zentalis Pharmaceuticals, Inc. reported that its Chief Medical Officer, Ingmar Bruns, received a grant of stock options on 01/08/2026. The award covers 365,000 stock options with an exercise price of $2.84 per share and an expiration date of 01/07/2036. Each option is exercisable for one share of common stock, giving potential access to 365,000 shares if exercised in the future.
According to the filing, the options were granted at a price of $0 for the derivative security itself and are held directly by the reporting person. The options will vest over four years in substantially equal monthly installments, as long as Bruns continues to serve with the company, so ownership rights build gradually rather than all at once.
Zentalis Pharmaceuticals, Inc. reported an insider equity award for its CEO and President, Julia Marie Eastland, in a Form 4 filing. On January 8, 2026, she received a grant of stock options to buy 775,000 shares of the company’s common stock at an exercise price of $2.84 per share. These options were reported as held directly, with 775,000 derivative securities beneficially owned following the transaction.
According to the filing, the options will vest over four years in substantially equal monthly installments, and vesting is conditioned on her continued service with the company. There were no sales of stock reported; this filing reflects an award of options rather than a disposition of shares.
Zentalis Pharmaceuticals reported a corporate update focused on its lead cancer drug candidate azenosertib and its financial position. In 2025 the company completed enrollment in Part 2a of its Phase 2 DENALI trial in platinum-resistant ovarian cancer, aligned with the FDA on the design of the confirmatory ASPENOVA Phase 3 trial, and reported strong data across three PROC trials supporting Cyclin E1-positive disease as the lead indication. As of September 30, 2025, Zentalis held $280.7 million in cash, cash equivalents and marketable securities and believes this provides runway into late 2027. For 2026, it expects DENALI Part 2a dose confirmation and ASPENOVA Phase 3 initiation in the first half of the year and a DENALI Part 2 topline readout by year end 2026, which it states could support a potential accelerated approval, subject to FDA feedback.